Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

3.840
-0.110-2.78%
Volume:95.96M
Turnover:371.14M
Market Cap:72.08B
PE:18.88
High:3.940
Open:3.900
Low:3.780
Close:3.950
Loading ...

Sino Biopharmaceutical - Global Collaboration Agreement With Biosion and Aclaris Therapeutics

THOMSON REUTERS
·
05 Dec 2024

Sino Biopharmaceutical Gets Chinese Regulator's Marketing Approval for Endometrial Cancer Drug

MT Newswires Live
·
27 Nov 2024

BRIEF-Sino Biopharmaceutical Receives Approval For Marketing Benmelstobart Injection In Combination With Anlotinib Hydrochloride Capsule

Reuters
·
27 Nov 2024

Sino Biopharmaceutical - Approval for Marketing of Benmelstobart Injection in Combination With Anlotinib Hydrochloride Capsule by Nmpa China

THOMSON REUTERS
·
27 Nov 2024

Sino Biopharmaceutical Submits New Indication Application for Liver Cancer Drug Combo

MT Newswires Live
·
21 Nov 2024

Sino Biopharmaceutical - Submitted a New Indication Application for Marketing to Cde for Anlotinib Hydrochloride Capsule

THOMSON REUTERS
·
21 Nov 2024

Sino Biopharm Injects 142 Million Yuan into LaNova Medicines

MT Newswires Live
·
20 Nov 2024

Greater China Stocks Close Mixed; Shanghai Leads Gainers

Dow Jones
·
20 Nov 2024

BUZZ-Sino Biopharmaceutical rises most in nearly 5 weeks on LaNova deal

Reuters
·
20 Nov 2024

BRIEF-Sino Biopharmaceutical Signs Equity Investment And Strategic Cooperation Agreement

Reuters
·
20 Nov 2024

Sino Biopharmaceutical - Signing Equity Investment and Strategic Cooperation Agreement With Lanova Medicines

THOMSON REUTERS
·
20 Nov 2024

Sino Biopharmaceutical - Deal for Lm-108 in Mainland China Region

THOMSON REUTERS
·
20 Nov 2024

Sino Biopharmaceutical's Fourth-Gen EGFR Inhibitor's IND Application Gets US FDA Nod

MT Newswires Live
·
15 Nov 2024

BRIEF-Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"

Reuters
·
14 Nov 2024

Sino Biopharmaceutical - Approval Granted for Clinical Trials of Egfr Inhibitor "Tqb3002" in US

THOMSON REUTERS
·
14 Nov 2024

The five-year shareholder returns and company earnings persist lower as Sino Biopharmaceutical (HKG:1177) stock falls a further 4.0% in past week

Simply Wall St.
·
12 Nov 2024

Sino Biopharmaceutical Cancer Drug Gets Marketing Approval in China

MT Newswires Live
·
11 Nov 2024

BRIEF-Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa

Reuters
·
11 Nov 2024

Sino Biopharmaceutical - Approval for Marketing of Kras G12c Inhibitor Garsorasib Tablet From Nmpa

THOMSON REUTERS
·
11 Nov 2024

Greater China Stocks Rise; Shanghai Sees Largest Increase

Dow Jones
·
04 Nov 2024